These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32684632)

  • 1. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
    Parting O; Langer S; Kuepper MK; Wessling C; Li S; Braunschweig T; Chatain N; Maié T; Costa IG; Crysandt M; Huber M; Brümmendorf TH; Koschmieder S; Schemionek M
    Leukemia; 2020 Oct; 34(10):2635-2647. PubMed ID: 32684632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling.
    Kuepper MK; Bütow M; Herrmann O; Ziemons J; Chatain N; Maurer A; Kirschner M; Maié T; Costa IG; Eschweiler J; Koschmieder S; Brümmendorf TH; Müller-Newen G; Schemionek M
    Leukemia; 2019 Aug; 33(8):1964-1977. PubMed ID: 30842608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
    Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
    Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
    Chen M; Turhan AG; Ding H; Lin Q; Meng K; Jiang X
    Oncotarget; 2017 Jul; 8(27):43662-43677. PubMed ID: 28599273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
    Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
    Burslem GM; Schultz AR; Bondeson DP; Eide CA; Savage Stevens SL; Druker BJ; Crews CM
    Cancer Res; 2019 Sep; 79(18):4744-4753. PubMed ID: 31311809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.
    Baquero P; Dawson A; Mukhopadhyay A; Kuntz EM; Mitchell R; Olivares O; Ianniciello A; Scott MT; Dunn K; Nicastri MC; Winkler JD; Michie AM; Ryan KM; Halsey C; Gottlieb E; Keaney EP; Murphy LO; Amaravadi RK; Holyoake TL; Helgason GV
    Leukemia; 2019 Apr; 33(4):981-994. PubMed ID: 30185934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
    Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y
    Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.
    Agarwal P; Zhang B; Ho Y; Cook A; Li L; Mikhail FM; Wang Y; McLaughlin ME; Bhatia R
    Blood; 2017 Feb; 129(8):1008-1020. PubMed ID: 28011678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel combination treatments targeting chronic myeloid leukemia stem cells.
    Al Baghdadi T; Abonour R; Boswell HS
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):94-105. PubMed ID: 22178144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.
    Agarwal P; Li H; Choi K; Hueneman K; He J; Welner RS; Starczynowski DT; Bhatia R
    Cell Rep; 2021 Jul; 36(2):109386. PubMed ID: 34260914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
    Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
    Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.